GLP-1 agonist-based therapies: An emerging new class of antidiabetic drug with potential cardioprotective effects

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Current Atherosclerosis Reports

• Publication date

  2009-02-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/S11883-009-0015-9PMID 19228481
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart.

  2008cited by this paper
• Three good reasons for heart surgeons to understand cardiac metabolism.

  2008cited by this paper
• Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat

  2008cited by this paper
• Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

  2008influential reference
• Cardioprotective and Vasodilatory Actions of Glucagon-Like Peptide 1 Receptor Are Mediated Through Both Glucagon-Like Peptide 1 Receptor–Dependent and –Independent Pathways

  2008cited by this paper
• Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study.

  2008cited by this paper
• Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride.

  2007cited by this paper
• Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting.

  2007cited by this paper
• Comment on: Evans JMM, Ogston SA, Emslie-Smith A, Morris AD (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930–936

  2006cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Dose–response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study

  2006cited by this paper
• Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat Hearts

  2006cited by this paper
• Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

  2006cited by this paper
• Realizing the clinical potential of ischemic preconditioning and postconditioning

  2005cited by this paper
• Myocardial substrate metabolism in the normal and failing heart.

  2005cited by this paper
• Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes

  2005cited by this paper
• Glucagon Like Peptide-1 is Protective Against Myocardial Ischemia/Reperfusion Injury when Given Either as a Preconditioning Mimetic or at Reperfusion in an Isolated Rat Heart Model

  2005cited by this paper
• Glucagon-Like Peptide-1 Limits Myocardial Stunning following Brief Coronary Occlusion and Reperfusion in Conscious Canines

  2005cited by this paper
• Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease.

  2005cited by this paper
• Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury.

  2005influential reference
• Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

  2004cited by this paper
• Ischemic preconditioning and preinfarction angina in the clinical arena

  2004cited by this paper
• Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy

  2004cited by this paper
• Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion

  2004cited by this paper
• Impact of diabetes mellitus on long-term outcome after unstable angina and non-ST-segment elevation myocardial infarction treated with a very early invasive strategy

  2004cited by this paper
• Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

  2004cited by this paper
• GLP-1 inhibition of pancreatic islet cell apoptosis.

  2004cited by this paper
• Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis*

  2003cited by this paper
• International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels

  2003cited by this paper
• Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium.

  2003cited by this paper
• Apoptosis as a therapeutic target in acutely ischemic myocardium

  2003cited by this paper
• International Union of Pharmacology. XXXV. The Glucagon Receptor Family

  2003cited by this paper
• Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway.

  2003cited by this paper
• Editorial: sulfonylureas differ in effects on ischemic preconditioning--is it time to retire glyburide?

  2003cited by this paper
• Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes.

  2002cited by this paper
• Switching Metabolic Genes to Build a Better Heart

  2002cited by this paper
• Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors.

  2002cited by this paper
• Protein Kinase Cζ Activation Mediates Glucagon-Like Peptide-1–Induced Pancreatic β-Cell Proliferation

  2001cited by this paper
• Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation.

  2001cited by this paper
• The Glucagon Receptor Family

  2000cited by this paper
• Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.

  1999cited by this paper
• Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss.

  1999cited by this paper
• Heterogeneity of pig intestinal D-glucose transport systems.

  1999cited by this paper
• Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men.

  1999cited by this paper
• Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss.

  1999cited by this paper
• Heterogeneity of pig intestinald-glucose transport systems.

  1999cited by this paper
• Effects of ACE inhibition on cardiomyocyte apoptosis in dogs with heart failure.

  1998cited by this paper
• Novel mechanisms in the treatment of heart failure: inhibition of oxygen radicals and apoptosis by carvedilol.

  1998cited by this paper
• Obesity as a disease.

  1997cited by this paper
• Maximum oxidative phosphorylation capacity of the mammalian heart.

  1997cited by this paper
• Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor.

  1996cited by this paper
• Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: case control study over three years

  1996cited by this paper
• Cardiac ATP-sensitive K+ channels: regulation by intracellular nucleotides and K+ channel-opening drugs.

  1995cited by this paper
• Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

  1995cited by this paper
• Postprandial lipoproteins and progression of coronary atherosclerosis.

  1994cited by this paper

• Clinical Evidence of Antidepressant Effects of Insulin and Anti-Hyperglycemic Agents and Implications for the Pathophysiology of Depression—A Literature Review

  2020cites this paper
• Computational insight into conformational states of glucagon-like peptide-1 receptor (GLP-1R) and its binding mode with GLP-1

  2016cites this paper
• chorego – stanowisko American Diabetes Association ( ADA ) i European Association for the Study of Diabetes ( EASD )

  2016cites this paper
• Glucagon-like peptide-1 receptor agonists as insulin add-on therapy in patients with inadequate glycemic control in type 2 diabetes mellitus: lixisenatide as a new therapeutic option.

  2015cites this paper
• The Importance of the Treatment Strategy Changes in the Long-Term Evolution of Type 2 Diabetic Patients with Sub-Optimal Glycaemic Control After Acute Coronary Syndrome

  2015cites this paper
• FORMACIÓN CONTINUADA. ACTUALIZACIÓN EN MEDICINA DE FAMILIA Seguridad cardiovascular de los antidiabéticos no insulínicos. Posicionamiento científico SEMERGEN

  2014cites this paper
• Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes

  2014cites this paper
• Dipeptidyl peptidase IV and Mortality After an Acute Heart Failure Episode

  2013cites this paper
• Untersuchung der Effekte des GLP-1 Systems auf Komponenten des Metabolischen Syndrom in vivo

  2013cites this paper
• Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies

  2013cites this paper
• Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2012cites this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cites this paper
• Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes

  2012cites this paper
• Focus on Incretin-Based Therapies: Targeting the Core Defects of Type 2 Diabetes

  2011cites this paper
• Cardiovascular effects of glucagonlike peptide-1 agonists.

  2011cites this paper
• Glucagon-like Peptide-1 (GLP-1), Immediately Prior to Reperfusion, Decreases Neutrophil Activation and Reduces Myocardial Infarct Size in Rodents

  2011cites this paper
• Incretin-Related Therapies in Type 2 Diabetes: A Practical Overview

  2011cites this paper
• Analysis of glucagon-like peptide 1; what to measure?

  2011cites this paper
• Emerging therapeutic approaches for the management of diabetes mellitus and macrovascular complications.

  2011cites this paper
• Inkretine: Gibt es kardiovaskuläre Effekte?

  2010cites this paper
• Defining and achieving treatment success in patients with type 2 diabetes mellitus.

  2010cites this paper
• Influence of glycemic control on the development of diabetic cardiovascular and kidney disease.

  2010cites this paper
• Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies

  2010cites this paper
• Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists.

  2009cites this paper
• Incretin‐based therapies: Therapeutic rationale and pharmacological promise for type 2 diabetes

  2009influential citation